CHMP recommend market authorisation for avapritinib (Ayvakyt)

This protein kinase inhibitor is intended to be licensed as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours harbouring the platelet-derived growth factor receptor alpha D842V mutation.

European Medicines Agency